A Phase I, Single-Center, Dose Escalation Trial of Heterologous Prime-Boost Vaccination With Ad5.F35-hGUCY2C-PADRE and Lm-GUCY2C Vaccines in Adults With Advanced Colorectal and Small Bowel Adenocarcinomas
Latest Information Update: 02 Mar 2026
At a glance
- Drugs Ad5.F35 hGCC PADRE (Primary) ; Listeria monocytogenes vaccine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
Most Recent Events
- 01 Mar 2026 New trial record